Performing both ELISpot and ICS assays requires a lot of starting material (PBMC isolated from whole blood), which might not be accessible. The question then arises: which method to use? ELISpot or ICS?
TORONTO (PRWEB) October 22, 2020
Efficacy in a vaccine trial is assessed through the production of protective antibodies against the infectious agent. Measurement of the neutralizing effect of these antibodies is performed through cell-based assays. Over the past years, additional assays have been introduced in vaccine trials in order to get a better understanding of the vaccine’s mode of action on the immune system. These assays allow for the monitoring of T-cell responses in subjects upon vaccination, including the humoral response (supported by CD4 helper T cells) and the elimination of infected cells by CD8 cytotoxic T cells (cellular response).
Flow cytometry and multimer detection can be used to follow an antigen specific T-cell response and reveal a specific TCR. However, this method allows one to follow only one antigen and the functional state (effector/anergic) of the cells remains unknown. Given these limitations, most trials now employ ELISpot and ICS to reveal both the antigen-specificity and the functionality of the immune response induced by the treatment.
Performing both ELISpot and ICS assays requires a lot of starting material (PBMC isolated from whole blood), which might not be accessible. The question then arises: which method to use? ELISpot or ICS? On one hand, the ELISpot is commonly considered more sensitive than the ICS assay while requiring less amount of PBMC. On the other hand, the ICS allows for the measurement of cytokines as well as surface and intracellular markers to generate a more complete cellular profile but consumes more of the precious PBMC material.
Join Philippe Pouliot, PhD, Director Development Team (Immunology), Caprion Biosciences Inc. in a live webinar on Thursday, October 29, 2020 at 11am EDT (4pm BST/UK).
For more information or to register for this event, visit ICS and ELISpot for The Study of Cell Response: Choosing the Optimal Method in Immuno-Oncology or COVID-19 Vaccination Trials.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
